A UK-German partnership is using quantum computing to find new drug targets for a hereditary heart condition that affects roughly 1 in 500 people. Hypertrophic cardiomyopathy (HCM) thickens the heart muscle, raising the risk of sudden cardiac events, yet current treatments are limited. The two small companies—CardiaTec and innoVitro—are combining quantum algorithms with lab-grown human heart cells that mimic the disease. The quantum analysis maps complex biological networks to pinpoint where the disease originates; those targets are then tested in engineered cells, keeping the work directly relevant to human biology. The project focuses on drug targets already linked to compounds that passed phase 1 safety trials but failed later-stage tests in other diseases. Because those compounds are known to be safe in humans, any validated target could move rapidly toward clinical use. If successful, the work would open new treatment pathways for HCM and create a significant commercial opportunity for both companies in the UK and German markets. This is applied research with a clear, near-term goal: turning computational discovery into a clinically viable therapy.
View original technical description
Hypertrophic cardiomyopathy (HCM) is a hereditary heart condition that affects approximately 1 in 500 individuals in the UK and Germany. Often leading to significant health challenges and an increased risk of sudden cardiac events, despite its prevalence, current treatment options are limited, and there is an urgent need to support the development of innovative, new therapeutic approaches. To help address this, UK SME CardiaTec and German SME innoVitro GmbH have embarked on a collaborative project to help improve HCM treatment. This project brings together CardiaTec's expertise in artificial intelligence (AI) and quantum computing with innoVitro's advanced cellular modelling capabilities and aims to identify new therapeutic targets for HCM by analysing complex biological networks using quantum algorithms and validating these findings through cutting-edge laboratory techniques. The project will begin by using quantum computing to analyse complex biological networks associated with HCM, identifying key areas that may contribute to the disease. These findings will then be tested in laboratory settings using human heart cells engineered to exhibit HCM characteristics. This approach ensures that the research is directly relevant to human health. Combining cutting-edge technology with biological expertise, this partnership seeks to uncover new pathways for treatment, offering hope to those affected by HCM and will unlock new markets and revenue opportunities in both geographic markets, crystallising a high-value collaboration. By focussing on drug targets already targeted by in-licencable clinical compounds which have failed later stage clinical trials in other indications (due to being applied in an incompatible disease are), but which have passed phase 1 clinical trials (and are therefore safe in humans) will progress CardiaTec rapidly towards treating patients in the clinic, and lead to a huge value inflection for the company.
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.
Is something wrong? Let us know